Vascular-targeted photodynamic therapy with padeliporfin (Tookad® Soluble)

Wolf S, Grössmann N
Record ID 32018000627
English
Authors' objectives: Prostate cancer is one of the most common types of cancer in men, with 1.4 million cases in 2016 globally. This systematic review aimed to analyse whether vascular-targeted photodynamic (VTP) therapy with padeliporfin is more effective and safer compared to active surveillance (AS) or radical therapies for low-risk prostate cancer.
Authors' results and conclusions: Overall, the level of evidence was rated as "low" to “moderate” for the outcomes of clinical effectiveness and safety. The current evidence is not sufficient to conclude that VTP therapy with padeliporfin is more effective and safer than AS. No studies comparing VTP therapy with padeliporfin to radical therapies were identified.
Authors' methods: In total, for the effectiveness analysis, one randomised controlled study (RCT) and its four-year follow-up (VTP therapy vs. AS) and for the safety analysis, one additional prospective single-arm study met the inclusion criteria and were extracted.
Authors' identified further research: We currently do not recommend the inclusion of the procedure in the Austrian hospital benefit catalogue. A re-evaluation is only recommended for intermediate-risk prostate cancer from 2030 onwards after an ongoing RCT has been completed.
Details
Project Status: Completed
URL for project: https://aihta.at/page/bewertung-medizinischer-einzelleistungen-mel-2019-1/en
Year Published: 2020
URL for published report: http://eprints.aihta.at/1258/1/DSD_123.pdf
URL for additional information: http://eprints.aihta.at/1258/
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: Austria
MeSH Terms
  • Prostatic Neoplasms
  • Phototherapy
  • Photosensitizing Agents
  • Vascular Access Devices
Keywords
  • Low-risk prostate cancer
  • vascular-targeted photodynamic therapy (VTP)
  • padeliporfin
  • clinical effectiveness
Contact
Organisation Name: Ludwig Boltzmann Institute for Health Technology Assessment
Contact Address: Ludwig Boltzmann Institute for fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7/rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99
Contact Name: tarquin.mittermayr@aihta.at
Contact Email: office@aihta.at
Copyright: Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.